Back close
Admissions

mFLOT versus EOX in first line treatment of metastatic carcinoma of stomach

Publication Type : Conference Proceedings

Publisher : Elsevier

Source : Annals of Oncology, Volume 29, Issue suppl_9, 1 November 2018, mdy432.015, https://doi.org/10.1093/annonc/mdy432.015

Url : https://www.sciencedirect.com/science/article/pii/S092375341943130X?via%3Dihub

Campus : Kochi

School : School of Medicine

Year : 2018

Abstract : Background: Al Batrans fluouracil/leucovorin/oxaliplatin/docetaxel (FLOT) chemotherapy has been shown to significantly improve survival outcomes in patients with advanced gastric cancer, but there is no head to head comparison with the EOX regimen which has been shown to have the highest median OS in the REAL-2 study. The purpose of this study was to compare the safety and efficacy of these two regimens.

Cite this Research Publication : Srinivasalu V K, Subramaniam N, Jose W, Philip A, Pavithran K (2018) mFLOT versus EOX in first line treatment of metastatic carcinoma of stomach. In: ESMO Asia 2018. Annals of Oncology, Volume 29, Issue suppl_9, 1 November 2018, mdy432.015, https://doi.org/10.1093/annonc/mdy432.015

Admissions Apply Now